WO1987000613A1
(en)
*
|
1985-07-19 |
1987-01-29 |
Armtech Limited |
A disc magazine firearm
|
US7863444B2
(en)
*
|
1997-03-19 |
2011-01-04 |
Abbott Laboratories |
4-aminopyrrolopyrimidines as kinase inhibitors
|
US7223724B1
(en)
|
1999-02-08 |
2007-05-29 |
Human Genome Sciences, Inc. |
Use of vascular endothelial growth factor to treat photoreceptor cells
|
US6921763B2
(en)
*
|
1999-09-17 |
2005-07-26 |
Abbott Laboratories |
Pyrazolopyrimidines as therapeutic agents
|
MXPA02003434A
(es)
*
|
2000-08-04 |
2002-09-02 |
Human Genome Sciences Inc |
Factor de crecimiento endotelial vascular 2.
|
MXPA03008560A
(es)
*
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos.
|
US20030176674A1
(en)
*
|
2001-04-13 |
2003-09-18 |
Rosen Craig A. |
Vascular endothelial growth factor 2
|
WO2002083704A1
(en)
*
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
US20050232921A1
(en)
*
|
2001-04-13 |
2005-10-20 |
Rosen Craig A |
Vascular endothelial growth factor 2
|
JP2004528349A
(ja)
|
2001-04-30 |
2004-09-16 |
グラクソ グループ リミテッド |
副腎皮質刺激ホルモン放出因子(crf)のアンタゴニストとしての縮合ピリミジン類
|
ES2309206T3
(es)
*
|
2001-10-02 |
2008-12-16 |
Smithkline Beecham Corporation |
Compuestos quimicos.
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
US20030225273A1
(en)
*
|
2002-03-21 |
2003-12-04 |
Michaelides Michael R. |
Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
|
US20030199525A1
(en)
*
|
2002-03-21 |
2003-10-23 |
Hirst Gavin C. |
Kinase inhibitors
|
US6695881B2
(en)
|
2002-04-29 |
2004-02-24 |
Alcon, Inc. |
Accommodative intraocular lens
|
US7652039B2
(en)
*
|
2002-05-17 |
2010-01-26 |
Sequella, Inc. |
Methods of use and compositions for the diagnosis and treatment of infectious disease
|
US7456222B2
(en)
*
|
2002-05-17 |
2008-11-25 |
Sequella, Inc. |
Anti tubercular drug: compositions and methods
|
US20040033986A1
(en)
*
|
2002-05-17 |
2004-02-19 |
Protopopova Marina Nikolaevna |
Anti tubercular drug: compositions and methods
|
AU2003261204A1
(en)
*
|
2002-07-23 |
2004-02-09 |
Smithkline Beecham Corporation |
Pyrazolopyrimidines as kinase inhibitors
|
WO2004009597A2
(en)
*
|
2002-07-23 |
2004-01-29 |
Smithkline Beecham Corporation |
Pyrazolopyrimidines as protein kinase inhibitors
|
JP2006514918A
(ja)
*
|
2002-07-23 |
2006-05-18 |
スミスクライン ビーチャム コーポレーション |
キナーゼインヒビターとしてのピラゾロピリミジン
|
AU2003246972A1
(en)
*
|
2002-08-06 |
2004-02-23 |
Astrazeneca Ab |
Condensed pyridines and pyrimidines with tie2 (tek) activity
|
GB0226370D0
(en)
*
|
2002-11-12 |
2002-12-18 |
Novartis Ag |
Organic compounds
|
GB0230089D0
(en)
*
|
2002-12-24 |
2003-01-29 |
Astrazeneca Ab |
Therapeutic agents
|
GEP20084540B
(en)
|
2003-01-14 |
2008-11-25 |
Arena Pharm Inc |
1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
US20050008640A1
(en)
*
|
2003-04-23 |
2005-01-13 |
Wendy Waegell |
Method of treating transplant rejection
|
US7429596B2
(en)
*
|
2003-06-20 |
2008-09-30 |
The Regents Of The University Of California |
1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
|
KR20060056944A
(ko)
*
|
2003-07-14 |
2006-05-25 |
아레나 파마슈티칼스, 인크. |
대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료
|
EP1670314A4
(en)
*
|
2003-09-05 |
2009-02-25 |
Sequella Inc |
METHODS AND COMPOSITIONS INCLUDE DIAMINE AS A NEW THERAPEUTIC FOR TUBERCULOSIS
|
BRPI0416243A
(pt)
|
2003-11-05 |
2007-01-09 |
Palingen Inc |
método de tratamento de um paciente humano que sofre de uma condição que inclui uma hiper-proliferação de células b; formulação farmacêutica para injeção parenteral; kit para o tratamento de um paciente que sofre de uma condição que inclui uma hiper-proliferação de células b; e método para purgar a medula óssea de um paciente que sofre de cáncer linfóide de células b malignas antes do reimplante da medula óssea no paciente após a terapia mieloablativa
|
GB0401334D0
(en)
*
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
WO2005074603A2
(en)
*
|
2004-02-03 |
2005-08-18 |
Abbott Laboratories |
Aminobenzoxazoles as therapeutic agents
|
AU2005219525B2
(en)
*
|
2004-02-27 |
2011-08-18 |
F. Hoffmann-La Roche Ag |
Fused derivatives of pyrazole
|
JP2007530453A
(ja)
*
|
2004-03-19 |
2007-11-01 |
ザ ペン ステート リサーチ ファウンデーション |
黒色腫を治療するためのコンビナトリアル法および組成物
|
WO2005112936A1
(en)
*
|
2004-05-14 |
2005-12-01 |
The Regents Of The University Of Michigan |
Compositions and methods relating to protein kinase inhibitors
|
WO2005117932A1
(en)
*
|
2004-06-04 |
2005-12-15 |
The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations |
Bisubstrate inhibitors of protein tyrosine kinases as therapeutic agents
|
US20110104186A1
(en)
|
2004-06-24 |
2011-05-05 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
AU2005304973A1
(en)
|
2004-11-05 |
2006-05-18 |
Palingen, Inc. |
Antibody induced cell membrane wounding
|
WO2006068760A2
(en)
|
2004-11-19 |
2006-06-29 |
The Regents Of The University Of California |
Anti-inflammatory pyrazolopyrimidines
|
DOP2006000009A
(es)
*
|
2005-01-13 |
2006-08-15 |
Arena Pharm Inc |
Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
|
WO2007029629A1
(ja)
|
2005-09-06 |
2007-03-15 |
Shionogi & Co., Ltd. |
Pgd2受容体アンタゴニスト活性を有するインドールカルボン酸誘導体
|
US20070072933A1
(en)
*
|
2005-09-26 |
2007-03-29 |
Peyman Gholam A |
Delivery of an ocular agent
|
AU2006316605B2
(en)
|
2005-11-17 |
2012-04-26 |
Osi Pharmaceuticals, Inc. |
Fused bicyclic mTOR inhibitors
|
WO2007064931A2
(en)
*
|
2005-12-02 |
2007-06-07 |
Bayer Healthcare Llc |
Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
|
PE20070855A1
(es)
*
|
2005-12-02 |
2007-10-14 |
Bayer Pharmaceuticals Corp |
Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
|
US8338594B2
(en)
*
|
2005-12-02 |
2012-12-25 |
Bayer Healthcare Llc |
Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
|
JP5512975B2
(ja)
*
|
2005-12-29 |
2014-06-04 |
アッヴィ・インコーポレイテッド |
タンパク質キナーゼ阻害薬
|
JP2009523724A
(ja)
|
2006-01-13 |
2009-06-25 |
ファーマサイクリクス,インコーポレイテッド |
チロシンキナーゼ阻害剤およびその使用方法
|
JP5207983B2
(ja)
*
|
2006-02-09 |
2013-06-12 |
アサーシス, インク. |
肥満および他のcns障害を治療するためのピラゾール類
|
CA2645137A1
(en)
|
2006-03-07 |
2007-09-13 |
James F. Blake |
Heterobicyclic pyrazole compounds and methods of use
|
KR20090017498A
(ko)
|
2006-04-04 |
2009-02-18 |
더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 |
Pi3 키나제 길항물질
|
NL2000613C2
(nl)
*
|
2006-05-11 |
2007-11-20 |
Pfizer Prod Inc |
Triazoolpyrazinederivaten.
|
GB0610242D0
(en)
*
|
2006-05-23 |
2006-07-05 |
Novartis Ag |
Organic compounds
|
SI2530083T1
(sl)
|
2006-09-22 |
2016-09-30 |
Pharmacyclics Llc |
Inhibitorji Bruton tirozin kinaze
|
ES2403546T3
(es)
|
2006-11-03 |
2013-05-20 |
Pharmacyclics, Inc. |
Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
|
WO2008079972A2
(en)
|
2006-12-20 |
2008-07-03 |
Bayer Healthcare Llc |
4-{4- [ ({3-tert-butyl-1- [3- (hydroxymethyl) phenyl] - 1h- pyrazol- 5 -yl } carbamoyl) -amin o] -3-chlorophenoxy} -n-methylpyridine-2-carboxamide as an inhibitor of the vegfr kinase for the treatment of cancer
|
SI2099442T1
(sl)
*
|
2006-12-26 |
2015-03-31 |
Pharmacyclics, Inc. |
Postopek uporabe inhibitorjev histon deacetilaze in spremljanje biomarkerjev v kombiniranjem zdravljenju
|
WO2008089307A2
(en)
*
|
2007-01-18 |
2008-07-24 |
Lexicon Pharmaceuticals, Inc. |
Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
|
WO2008089310A2
(en)
*
|
2007-01-18 |
2008-07-24 |
Lexicon Pharmaceuticals, Inc. |
Delta 5 desaturase inhibitors for the treatment of obesity
|
ES2562215T3
(es)
|
2007-03-28 |
2016-03-03 |
Pharmacyclics Llc |
Inhibidores de la tirosina quinasa de Bruton
|
US8809273B2
(en)
|
2007-03-28 |
2014-08-19 |
Pharmacyclics, Inc. |
Inhibitors of Bruton's tyrosine kinase
|
US20100190777A1
(en)
|
2007-07-17 |
2010-07-29 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
WO2009025478A1
(en)
*
|
2007-08-17 |
2009-02-26 |
Lg Life Sciences Ltd. |
Indole and indazole compounds as an inhibitor of cellular necrosis
|
GB2467670B
(en)
|
2007-10-04 |
2012-08-01 |
Intellikine Inc |
Chemical entities and therapeutic uses thereof
|
SG10201605472WA
(en)
|
2008-01-04 |
2016-09-29 |
Intellikine Llc |
Certain Chemical Entities, Compositions And Methods
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
US20110020326A1
(en)
*
|
2008-03-04 |
2011-01-27 |
Children's Medical Center Corporation |
Method of treating polycystic kidney disease
|
US8637542B2
(en)
|
2008-03-14 |
2014-01-28 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
WO2009114874A2
(en)
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Benzothiazole kinase inhibitors and methods of use
|
WO2009136965A1
(en)
*
|
2008-05-06 |
2009-11-12 |
Sequella, Inc. |
Compositions and methods comprising capuramycin analogues
|
US20090301928A1
(en)
*
|
2008-06-05 |
2009-12-10 |
United Comb & Novelty Corporation |
Packaging For Lipped Containers
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
KR20110039326A
(ko)
|
2008-07-08 |
2011-04-15 |
인텔리카인, 인크. |
키나제 억제제 및 사용 방법
|
US8946239B2
(en)
|
2008-07-10 |
2015-02-03 |
Duquesne University Of The Holy Spirit |
Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
|
AU2009270856B2
(en)
|
2008-07-16 |
2013-07-25 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
|
EP2346508B1
(en)
|
2008-09-26 |
2016-08-24 |
Intellikine, LLC |
Heterocyclic kinase inhibitors
|
WO2010045542A2
(en)
*
|
2008-10-16 |
2010-04-22 |
The Regents Of The University Of California |
Fused ring heteroaryl kinase inhibitors
|
US8476431B2
(en)
|
2008-11-03 |
2013-07-02 |
Itellikine LLC |
Benzoxazole kinase inhibitors and methods of use
|
US20100113472A1
(en)
*
|
2008-11-03 |
2010-05-06 |
Chemocentryx, Inc. |
Compounds for the treatment of osteoporosis and cancers
|
EP2419103A1
(en)
*
|
2009-04-15 |
2012-02-22 |
Fondazione IRCCS Istituto Nazionale dei Tumori |
Use of multi-kinase inhibitors in the treatment of vascular hyperpermeability
|
EP2427195B1
(en)
|
2009-05-07 |
2019-05-01 |
Intellikine, LLC |
Heterocyclic compounds and uses thereof
|
CA2771532C
(en)
|
2009-08-17 |
2021-03-23 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
CN102482283A
(zh)
*
|
2009-08-28 |
2012-05-30 |
阵列生物制药公司 |
Raf抑制剂化合物及其使用方法
|
US7741330B1
(en)
*
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
WO2011047384A2
(en)
|
2009-10-16 |
2011-04-21 |
The Regents Of The University Of California |
Methods of inhibiting ire1
|
EP2937345B1
(en)
|
2009-12-29 |
2018-03-21 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
WO2011094008A1
(en)
|
2010-01-27 |
2011-08-04 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
|
CN102918042B
(zh)
|
2010-02-08 |
2016-03-09 |
默沙东有限责任公司 |
8-甲基-1-苯基-咪唑[1,5-a]吡嗪化合物
|
WO2011146882A1
(en)
|
2010-05-21 |
2011-11-24 |
Intellikine, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
US9096531B2
(en)
|
2010-05-24 |
2015-08-04 |
Toa Eiyo Ltd. |
Fused imidazole derivative
|
EP2575818A4
(en)
|
2010-06-03 |
2013-11-06 |
Pharmacyclics Inc |
USE OF INHIBITORS OF BRUTON TYROSINE KINASE (BTK)
|
CN103221410B
(zh)
|
2010-09-22 |
2017-09-15 |
艾尼纳制药公司 |
Gpr119受体调节剂和对与其相关的障碍的治疗
|
CN103298474B
(zh)
|
2010-11-10 |
2016-06-29 |
无限药品股份有限公司 |
杂环化合物及其用途
|
AR084824A1
(es)
|
2011-01-10 |
2013-06-26 |
Intellikine Inc |
Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
|
US8889684B2
(en)
*
|
2011-02-02 |
2014-11-18 |
Boehringer Ingelheim International Gmbh |
Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
|
CN103491962B
(zh)
|
2011-02-23 |
2016-10-12 |
因特利凯有限责任公司 |
激酶抑制剂的组合及其用途
|
EP2710005B1
(en)
|
2011-05-17 |
2016-10-05 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
US9376438B2
(en)
|
2011-05-17 |
2016-06-28 |
Principia Biopharma, Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
CA2840687C
(en)
|
2011-07-01 |
2020-04-28 |
Dana-Farber Cancer Institute, Inc. |
Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma
|
KR20140048968A
(ko)
|
2011-07-13 |
2014-04-24 |
파마시클릭스, 인코포레이티드 |
브루톤형 티로신 키나제의 억제제
|
CA2842190A1
(en)
|
2011-07-19 |
2013-01-24 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
US8969363B2
(en)
|
2011-07-19 |
2015-03-03 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
EP2548877A1
(en)
*
|
2011-07-19 |
2013-01-23 |
MSD Oss B.V. |
4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
|
RU2014111823A
(ru)
|
2011-08-29 |
2015-10-10 |
Инфинити Фармасьютикалз, Инк. |
Гетероциклические соединения и их применения
|
CA2846496C
(en)
|
2011-09-02 |
2020-07-14 |
The Regents Of The University Of California |
Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
|
CN103917231B
(zh)
|
2011-09-13 |
2016-09-28 |
药品循环有限责任公司 |
组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途
|
WO2013074986A1
(en)
|
2011-11-17 |
2013-05-23 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
JP6335796B2
(ja)
|
2012-02-08 |
2018-06-06 |
アイジーエム バイオサイエンシズ インク.Igm Biosciences Inc. |
Cdim結合タンパク質及びその使用
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
BR112014029718A2
(pt)
*
|
2012-05-31 |
2017-06-27 |
Pharmascience Inc |
inibidores da proteína quinase
|
KR20220093389A
(ko)
|
2012-06-04 |
2022-07-05 |
파마싸이클릭스 엘엘씨 |
브루톤 타이로신 키나아제 저해제의 결정 형태
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
GB201211309D0
(en)
*
|
2012-06-26 |
2012-08-08 |
Fujifilm Mfg Europe Bv |
Process for preparing membranes
|
JP6575950B2
(ja)
|
2012-07-24 |
2019-09-18 |
ファーマサイクリックス エルエルシー |
Bruton型チロシンキナーゼ(Btk)阻害剤に対する耐性を伴う変異
|
EP2878601B1
(en)
|
2012-07-27 |
2018-03-28 |
Riken |
Agent for treating or controlling recurrence of acute myelogenous leukemia
|
ME03455B
(me)
|
2012-09-10 |
2020-01-20 |
Principia Biopharma Inc |
Jedinjenja pirazolopirimidina kao inhibitori kinaze
|
KR20150061651A
(ko)
|
2012-09-26 |
2015-06-04 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
Ire1의 조절
|
WO2014063068A1
(en)
|
2012-10-18 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
US9758522B2
(en)
*
|
2012-10-19 |
2017-09-12 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
US10000483B2
(en)
|
2012-10-19 |
2018-06-19 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
|
PE20151495A1
(es)
|
2012-11-15 |
2015-10-23 |
Pharmacyclics Inc |
Compuestos de pirrolopirimidina como inhibidores de quinasas
|
US9422314B2
(en)
|
2012-12-07 |
2016-08-23 |
VenatoRx Pharmaceuticals, Inc. |
Beta-lactamase inhibitors
|
CN105101970B
(zh)
|
2013-01-10 |
2018-11-20 |
维纳拓尔斯制药公司 |
β-内酰胺酶抑制剂
|
WO2014122474A1
(en)
|
2013-02-07 |
2014-08-14 |
Takeda Pharmaceutical Company Limited |
Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
|
HUE058914T2
(hu)
*
|
2013-03-15 |
2022-09-28 |
Janssen Pharmaceutica Nv |
Gyógyszer elõállítására szolgáló eljárások és köztitermékek
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
EP2976086B1
(en)
|
2013-03-22 |
2020-10-14 |
Millennium Pharmaceuticals, Inc. |
Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
KR101793807B1
(ko)
|
2013-04-25 |
2017-11-03 |
베이진 엘티디 |
단백질 키나제 억제제로서의 융합된 헤테로시클릭 화합물
|
JP6800750B2
(ja)
|
2013-08-02 |
2020-12-16 |
ファーマサイクリックス エルエルシー |
固形腫瘍の処置方法
|
WO2015023703A1
(en)
|
2013-08-12 |
2015-02-19 |
Pharmacyclics, Inc. |
Methods for the treatment of her2 amplified cancer
|
EP4130044A1
(en)
|
2013-09-13 |
2023-02-08 |
BeiGene Switzerland GmbH |
Anti-pd1 antibodies and their use as therapeutics and diagnostics
|
BR112016006978A2
(pt)
|
2013-09-30 |
2017-08-01 |
Pharmacyclics Llc |
inibidores de tirosina quinase de bruton
|
MY175778A
(en)
|
2013-10-04 |
2020-07-08 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
AU2014337044A1
(en)
|
2013-10-18 |
2016-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
CA2927917C
(en)
|
2013-10-18 |
2022-08-09 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of proliferative diseases
|
EP3060218A4
(en)
|
2013-10-25 |
2017-07-19 |
Pharmacyclics LLC |
Methods of treating and preventing graft versus host disease
|
JP6162904B2
(ja)
*
|
2014-02-03 |
2017-07-12 |
カディラ ヘルスケア リミティド |
新規複素環式化合物
|
US10449210B2
(en)
*
|
2014-02-13 |
2019-10-22 |
Ligand Pharmaceuticals Inc. |
Prodrug compounds and their uses
|
ES2841248T3
(es)
|
2014-02-21 |
2021-07-07 |
Principia Biopharma Inc |
Sales y forma sólida de un inhibidor de BTK
|
SG11201607705XA
(en)
|
2014-03-19 |
2016-10-28 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
WO2015143400A1
(en)
|
2014-03-20 |
2015-09-24 |
Pharmacyclics, Inc. |
Phospholipase c gamma 2 and resistance associated mutations
|
WO2015160975A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
US9862688B2
(en)
|
2014-04-23 |
2018-01-09 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
GB201410430D0
(en)
|
2014-06-11 |
2014-07-23 |
Redx Pharma Ltd |
Compounds
|
KR102130600B1
(ko)
|
2014-07-03 |
2020-07-08 |
베이진 엘티디 |
Pd-l1 항체와 이를 이용한 치료 및 진단
|
AU2015296215A1
(en)
|
2014-08-01 |
2017-03-23 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
KR20170033358A
(ko)
|
2014-08-07 |
2017-03-24 |
파마싸이클릭스 엘엘씨 |
브루톤 티로신 키나아제 저해제의 신규한 제제
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
ITRM20140620A1
(it)
|
2014-10-30 |
2016-04-30 |
Lead Discovery Siena S R L |
Compounds and uses thereof
|
UY36390A
(es)
*
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
|
JP2017538678A
(ja)
|
2014-11-05 |
2017-12-28 |
フレクサス・バイオサイエンシーズ・インコーポレイテッドFlexus Biosciences, Inc. |
免疫調節剤
|
CN104478884A
(zh)
*
|
2014-12-05 |
2015-04-01 |
广东东阳光药业有限公司 |
一种中间体的制备方法
|
BR112017013022A2
(pt)
|
2014-12-18 |
2018-02-27 |
Principia Biopharma Inc |
métodos para tratar uma doença inflamatória e/ou autoimune aguda num mamífero que a necessite onde a terapia de corticosteróides é utilizada como terapia de primeira ou segunda linha e/ou para tratar uma doença inflamatória e/ou autoimune num mamífero que a necessite, onde a terapia de corticosteróides é utilizada como terapia de manutenção de primeira ou segunda linha e/ou para eliminar ou reduzir dose terapêutica de corticosteróides utilizado no tratamento de uma doença inflamatória e/ou autoimune num mamífero que a necessite, onde a terapia de corticosteróides é utilizada como terapia de manutenção crônica de primeira ou segunda linha e/ou de tratamento de uma doença autoimune e/ou inflamatória num mamífero que a necessite
|
US10167451B2
(en)
|
2014-12-22 |
2019-01-01 |
The Chinese University Of Hong Kong |
Combinational use of mechanical manipulation and programin derivatives to increase Oct4, Sox2, or Nanog expression in fibroblasts
|
JP6736253B2
(ja)
*
|
2014-12-22 |
2020-08-05 |
ザ チャイニーズ ユニバーシティ オブ ホンコン |
体細胞から多能性幹細胞を作製するための機械的操作とプログラミンの併用
|
WO2016105528A2
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
NZ734220A
(en)
|
2015-01-06 |
2022-01-28 |
Arena Pharm Inc |
Methods of treating conditions related to the s1p1 receptor
|
CN105777755A
(zh)
*
|
2015-01-07 |
2016-07-20 |
常州百敖威生物科技有限公司 |
一种伊鲁替尼中间体3-碘-1h-吡唑并[3,4-d]嘧啶-4-胺的制备方法
|
DK3265084T3
(da)
|
2015-03-03 |
2024-02-12 |
Pharmacyclics Llc |
Farmaceutiske formuleringer af Bruton's tyrosinkinase-hæmmer
|
AU2016243529B2
(en)
|
2015-03-27 |
2021-03-25 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
US10702527B2
(en)
|
2015-06-12 |
2020-07-07 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
IL285890B
(en)
|
2015-06-22 |
2022-07-01 |
Arena Pharm Inc |
Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid
|
US20180305350A1
(en)
|
2015-06-24 |
2018-10-25 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
AU2016319125B2
(en)
|
2015-09-09 |
2021-04-08 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
JP6980649B2
(ja)
|
2015-09-14 |
2021-12-15 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
イソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法
|
EA201890730A1
(ru)
|
2015-09-16 |
2018-10-31 |
Локсо Онколоджи, Инк. |
Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
|
PE20220502A1
(es)
|
2015-12-16 |
2022-04-07 |
Loxo Oncology Inc |
Compuestos utiles como inhibidores de cinasa
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
EP3474856B1
(en)
|
2016-06-24 |
2022-09-14 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
JP7129704B2
(ja)
|
2016-06-29 |
2022-09-02 |
プリンシピア バイオファーマ インコーポレイテッド |
2-[3-[4-アミノ-3-(2-フルオロ-4-フェノキシ-フェニル)ピラゾロ[3,4-d]ピリミジン-1-イル]ピペリジン-1-カルボニル]-4-メチル-4-[4-(オキセタン-3-イル)ピペラジン-1-イル]ペント-2-エネニトリルの放出調節製剤
|
AU2017293423B2
(en)
|
2016-07-05 |
2023-05-25 |
Beigene, Ltd. |
Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
|
WO2018033853A2
(en)
|
2016-08-16 |
2018-02-22 |
Beigene, Ltd. |
Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
|
WO2018033135A1
(en)
|
2016-08-19 |
2018-02-22 |
Beigene, Ltd. |
Use of a combination comprising a btk inhibitor for treating cancers
|
WO2018137681A1
(en)
|
2017-01-25 |
2018-08-02 |
Beigene, Ltd. |
Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
|
JP2020507611A
(ja)
|
2017-02-16 |
2020-03-12 |
アリーナ ファーマシューティカルズ, インコーポレイテッド |
原発性胆汁性胆管炎の治療のための化合物および方法
|
CA3066518A1
(en)
|
2017-06-26 |
2019-01-03 |
Beigene, Ltd. |
Immunotherapy for hepatocellular carcinoma
|
WO2019034009A1
(en)
|
2017-08-12 |
2019-02-21 |
Beigene, Ltd. |
BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
|
US11786529B2
(en)
|
2017-11-29 |
2023-10-17 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
|
CN108299311A
(zh)
*
|
2018-02-28 |
2018-07-20 |
杭州福斯特药业有限公司 |
一种5-溴-2-氯-n-环戊基嘧啶-4-胺的制备方法
|
CN111171035B
(zh)
*
|
2018-11-13 |
2021-03-30 |
山东大学 |
4-苯氧基苯基吡唑并嘧啶酰胺衍生物的制备方法和应用
|
CN111454268B
(zh)
*
|
2019-01-18 |
2023-09-08 |
明慧医药(上海)有限公司 |
作为布鲁顿酪氨酸激酶抑制剂的环状分子
|
US20220372017A1
(en)
*
|
2019-06-24 |
2022-11-24 |
Dana-Farber Cancer Institute, Inc. |
Hck degraders and uses thereof
|
CN110511225B
(zh)
*
|
2019-08-19 |
2023-07-18 |
杭州中美华东制药有限公司 |
一种伊布替尼中间体的合成方法
|
WO2021038540A1
(en)
|
2019-08-31 |
2021-03-04 |
Sun Pharma Advanced Research Company Limited |
Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
|
EP4031547A1
(en)
|
2019-09-18 |
2022-07-27 |
Takeda Pharmaceutical Company Limited |
Plasma kallikrein inhibitors and uses thereof
|
KR20220098732A
(ko)
*
|
2019-10-08 |
2022-07-12 |
다나-파버 캔서 인스티튜트 인크. |
요법, 특히 myd88 돌연변이된 질환에 사용하기 위한 hck 억제제로서의 피라졸로피리미딘 유도체
|
CN112961158B
(zh)
*
|
2020-03-05 |
2022-07-01 |
四川大学华西医院 |
氨基嘧啶并吡唑/吡咯类衍生物及其制备方法和用途
|
AU2020436612A1
(en)
*
|
2020-03-16 |
2022-09-01 |
Flash Therapeutics, Llc |
Compounds for treating or inhibiting recurrence of acute myeloid leukemia
|
US11912668B2
(en)
|
2020-11-18 |
2024-02-27 |
Deciphera Pharmaceuticals, Llc |
GCN2 and perk kinase inhibitors and methods of use thereof
|
EP4308229A1
(en)
*
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Inhibitors of plasma kallikrein
|
US11786531B1
(en)
|
2022-06-08 |
2023-10-17 |
Beigene Switzerland Gmbh |
Methods of treating B-cell proliferative disorder
|
CN115650986A
(zh)
*
|
2022-10-22 |
2023-01-31 |
浙江工业大学 |
肉桂酰氨基吡唑并[3,4-d]嘧啶类化合物及其制备和应用
|